UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net income	$ 46,642	$ 71,608
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Stock-based compensation expense	6,074	5,579
Impairment of intangible assets	0	58,710
Inventory obsolescence charge	485	11,681
Income tax expense	7,617	3,381
Depreciation and amortization expense	732	3,300
Non-cash lease expense	240	0
Non-cash interest expense	342	1,352
Fair value adjustment related to warrant and CVR liability	5,440	(4,127)
Accretion on investments	(1,219)	(1,060)
Fair value adjustment related to investments	356	5
Loss on extinguishment of debt	2,756	0
Loss on derivative liability	7,216	0
Cash paid to settle derivative instrument and payoff premium	(9,016)	0
Settlement of royalties to Aquestive	(4,893)	0
Paid-in-kind interest	(3,134)	0
Gain on sale of future royalties, intellectual property, and other assets, net	(43,314)	0
Consulting fees paid in common stock	0	75
(Gain) loss on foreign currency exchange rates	(1,809)	131
Gain on sale of PRV	0	(148,325)
Change in assets and liabilities:
Accounts and other receivables	1,150	(6,969)
Prepaid expenses and other current assets	2,202	(296)
Inventories	(325)	(586)
Other long-term assets	45	0
Operating lease right-of-use assets	(234)	(798)
Accounts payable and accrued expenses	1,791	(11,269)
Discount and rebate liabilities	3,457	6,359
Operating lease liabilities	(234)	746
Other liabilities	807	(1,320)
Net cash provided by (used in) operating activities	23,174	(11,823)
Cash flows from investing activities:
Sale of future royalties, intellectual property, and other assets, net	48,935	0
Purchases of property and equipment	(252)	(312)
Purchases of investments	(80,836)	(157,712)
Sales and maturities of investments	143,222	30,500
Proceeds from sale of PRV	0	150,000
Net cash provided by investing activities	111,069	22,476
Cash flows from financing activities:
Repayment of debt	(60,092)	0
Payments for employee taxes related to stock awards	(1,485)	0
Proceeds from Employee Stock Purchase Plan	434	413
Proceeds from issuance of common stock for options exercised	753	2,947
Proceeds from issuance of common stock for warrants exercised	9,171	0
Payments of principal on insurance financing arrangements	0	(372)
Net cash (used in) provided by financing activities	(51,219)	2,988
Effect of exchange rate changes on cash and cash equivalents	(109)	286
Net increase in cash and cash equivalents	82,915	13,927
Cash and cash equivalents, beginning of period	62,406	33,785
Cash and cash equivalents, end of period	145,321	47,712
Supplemental cash flow information:
Cash paid for interest	1,370	2,626
Right-of-use assets obtained in exchange for lease liabilities	460	1,115
Cash paid for income taxes	$ 3,178	$ 0

The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.

Name:	us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- References

No definition available.